

Pragmatic Implementation Science to Assess Lipid Optimization in Peripheral Artery Disease: Primary Results of the OPTIMIZE PAD-1 Trial



Connie N. Hess, MD, MHS,^{1,2} Mark R. Nehler, MD,^{1,2} Ashley Daffron, PharmD,¹ Justin T. Morrison, MD,¹ Cullen E. Buchanan, MD,³ Joseph J. Saseen, PharmD,¹ Victoria E. Anderson,² Christopher P. Cannon, MD,^{2,4} Judith Hsia, MD,^{1,2} Marc P. Bonaca, MD, MPH^{1,2}

¹University of Colorado School of Medicine; ²CPC Clinical Research; ³Medical College of Wisconsin; ⁴Harvard Medical School


BACKGROUND

- Reducing low-density lipoprotein cholesterol (LDL-C) in peripheral artery disease (PAD) lowers risk of ischemic events¹
- Lipid-lowering therapies are underused in PAD²
- Implementation science aims to improve this gap, but few randomized trials exist

¹Bonaca MP, et al. Circulation 2018;137:338-350 ²Hess CN, et al. J Am Coll Cardiol 2021;77:3016-3027

STUDY DESIGN

Figure 1. OPTIMIZE PAD-1 Study Design




*6-minute walk test (6MWT) results to be reported separately


1º objective: To evaluate the efficacy of an interprofessional vascular care team including a clinical pharmacist and an intensive algorithmbased approach for lipid management versus usual care supplemented with provider education


Key eligibility criteria: Patients with non-coronary arterial disease cared for at University of Colorado with goal LDL-C <70 mg/dl per ACC/AHA guidelines and screening LDL-C ≥70 mg/dl

RESULTS



*trial ongoing







IQR, interquartile range ¹Calculated among patients with PAD ³Defined as any two of the following: coronary artery disease, cerebrovascular disease, or

peripheral artery disease *Defined as non-coronary, non-cerebrovascular, and non-lower extremity arterial disease *n-value 40.05









Error bars indicate the upper limit of the 95% confidence interval

Figure 5. Temporal Trend in LDL-C Level





Figure 6. Proportion of Subjects at Goal LDL-C



LIMITATIONS

OPTIMIZE PAD-1 was conducted at a single site

CONCLUSIONS

- LDL-C levels were not at goal for ~3/4 of patients with vascular disease, and statins and ezetimibe were used at baseline in 51% and 8%, respectively
- No increase in use of combination lipid lowering therapies was observed over 12 months in the Usual Care group
- Interprofessional care with an algorithm using multiple agents designed to achieve goal LDL-C in one step is effective for improving lipid management in vascular disease
- The interventional arm achieved LDL-C <55 mg/dl within 1 month with significantly more individuals at goal
- Results were achieved with drug obtained using standard insurance/payers rather than provided through the study

IMPLICATIONS

 OPTIMIZE PAD-1 demonstrates that healthcare systems can achieve better lipid management through use of a Vascular Care Team, leveraging an interprofessional model with pharmacy support and algorithm-based care

DISCLOSURES

Funding for OPTIMIZE PAD-1 was provided by research grants from Amgen. Inc and the America College of Cardiology Foundation. CNH, MRN, VEA, CPC, JH, and MPB receive salary support from CPC Clinical Research, a non-profit academic research organization affiliated with the University of Colorado, that receives or has received research grant/consulting funding between February 2021 and February 2023 from the following organizations: Abbott Laboratories, Adami Pharmaceuticals Corporation, Agios Pharmaceuticals, Inc., Alexion Pharma, Alnylam Pharmaceuticals, Inc., Amgen Inc., Angionetics, Inc., ARCA Biopharma, Inc., Array BioPharma Inc., AstraZeneca and Affiliates, Atentiv LLC, Audentes Therapeutics, Inc., Baver and Affiliates neur harat Deaconess Medical Center, Better Therapeutics, Inc., BIDMC, Boston Clinical Research Institute, Bristol-Meyers Squibb Company, Cambrian Biopharma, Inc., Cardiol Therapeutics Inc., CellResearch Corp., Cook Medical Incorporated, Covance, CSL Behring LLC, Network Control (Control Control Co Eidos Therapeutics, inc., EP Trading Co. Ltd., EPG Communication Holdings Ltd., Epizon Pharma Inc., Esperion Therapeutics, Inc., Everly Well, Inc., Exicon Consulting TvL. Ltd., Faraday Pharmaceuticas, Inc., Foresee Pharmaceuticals Co. Ltd., Fortress Biolech, Inc., HDL Therapeutics Inc., HeartFlow Inc., Hummingbird Bioscience, Insmed Inc., Ionis Pharmaceuticals Thetapeous Inc., retaintow Inc., nothiningiyou boxetince, insineto inc., idins r farmaceburas, IQVIA inc., JanOne Botech Holdings Inc., Janssen and Affiliates, Kaneka, Kowa Research Institute, Inc., Kyushu University, Lexicon Pharmaceuticals, inc., LOS Kyushu University, Mediminune Lid., Medpace, Merck à Affiliates, Novarits Pharmaceuticals Corp., Novale Medical, Ltd., Novo Nordisk, Inc., Pan Industry Group, Pfizer Inc., PhaseBio Pharmaceuticals, Inc., PPE Development, LP, Prairie Education and Research Cooperative, Prothena Biosciences Limited, Regeneron Pharmaceuticals, Inc., Regio Biosciences, Inc., Rexgenero, Saniff Interapeutics S.A. Sanofi-Aventi Scrupe, Silence Therapeutics PLC, Smith & Nephew pLc, Stealth BioTherapeutics Line, State of Colorado CCPD Orant, The Brigham & Women's Hospital, Inc., The Forinstein Institutes for Medical Research, Thrombosis Research Institute, University of Colorado, University of Pittsburgh, VarmX, Virta Health Corporation, WCTAtlas, Worldwide Clinical Trials Inc., WraSer, LC, and Yale Cardiovascular Research Group. JH also reports owning AstraZeneca stock. MPB receives support from the AHA SFRN under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project) and reports stock in Medironic and Pfizer. CPC also reports research grants from Amgen, Better Therapeutics, Boehringer-Ingelheir Dailchi Sankyo, Merck, Novo Nordisk, Pfizer and consulting fees from Amryt, Anrylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Biogen, BI, BMS, Eli Lilly, Janssen, Lexicon, Merck, r, Rhoshan, Sanofi. AD, JTM, CEB, and JJS report no disclosures.

